1
|
Bhattacharjee A, Jana A, Bhattacharjee S, Mitra S, De S, Alghamdi BS, Alam MZ, Mahmoud AB, Al Shareef Z, Abdel-Rahman WM, Woon-Khiong C, Alexiou A, Papadakis M, Ashraf GM. The role of Aquaporins in tumorigenesis: implications for therapeutic development. Cell Commun Signal 2024; 22:106. [PMID: 38336645 PMCID: PMC10854195 DOI: 10.1186/s12964-023-01459-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 12/25/2023] [Indexed: 02/12/2024] Open
Abstract
Aquaporins (AQPs) are ubiquitous channel proteins that play a critical role in the homeostasis of the cellular environment by allowing the transit of water, chemicals, and ions. They can be found in many different types of cells and organs, including the lungs, eyes, brain, glands, and blood vessels. By controlling the osmotic water flux in processes like cell growth, energy metabolism, migration, adhesion, and proliferation, AQPs are capable of exerting their regulatory influence over a wide range of cellular processes. Tumour cells of varying sources express AQPs significantly, especially in malignant tumours with a high propensity for metastasis. New insights into the roles of AQPs in cell migration and proliferation reinforce the notion that AQPs are crucial players in tumour biology. AQPs have recently been shown to be a powerful tool in the fight against pathogenic antibodies and metastatic cell migration, despite the fact that the molecular processes of aquaporins in pathology are not entirely established. In this review, we shall discuss the several ways in which AQPs are expressed in the body, the unique roles they play in tumorigenesis, and the novel therapeutic approaches that could be adopted to treat carcinoma.
Collapse
Affiliation(s)
- Arkadyuti Bhattacharjee
- Morningside Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, USA
| | - Ankit Jana
- Department of Biological Sciences, National University of Singapore, Singapore, 117558, Singapore
| | - Swagato Bhattacharjee
- KoshKey Sciences Pvt Ltd, Canara Bank Layout, Karnataka, Bengaluru, Rajiv Gandhi Nagar, Kodigehalli, 560065, India
| | - Sankalan Mitra
- KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India
| | - Swagata De
- Department of English, DDE Unit, The University of Burdwan, Golapbag, Burdwan, West Bengal, 713104, India
| | - Badrah S Alghamdi
- Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
- Pre-clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Mohammad Zubair Alam
- Pre-clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ahmad Bakur Mahmoud
- College of Applied Medical Sciences, Taibah University, Almadinah, Almunwarah, 71491, Saudi Arabia
| | - Zainab Al Shareef
- College of Medicine, and Research Institute for Medical and Health Sciences, Department of Basic Medical Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates
| | - Wael M Abdel-Rahman
- College of Health Sciences, and Research Institute for Medical and Health Sciences, Department of Medical Laboratory Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates
| | - Chan Woon-Khiong
- Department of Biological Sciences, National University of Singapore, Singapore, 117558, Singapore.
| | - Athanasios Alexiou
- University Centre for Research & Development, Chandigarh University, Chandigarh-Ludhiana Highway, Mohali, Punjab, India
- Department of Research & Development, Funogen, Athens, Greece
- Department of Research & Development, AFNP Med, 1030, Wien, Austria
- Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, NSW, 2770, Australia
| | - Marios Papadakis
- Department of Surgery II, University Hospital Witten-Herdecke, Heusnerstrasse 40, University of Witten-Herdecke, 42283, Wuppertal, Germany.
| | - Ghulam Md Ashraf
- College of Health Sciences, and Research Institute for Medical and Health Sciences, Department of Medical Laboratory Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates.
| |
Collapse
|
2
|
Kumar P, Woon-Khiong C. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr Gene Ther 2011; 11:144-53. [PMID: 21291355 DOI: 10.2174/156652311794940782] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Accepted: 12/10/2010] [Indexed: 11/22/2022]
Abstract
Classical non-viral methods of gene transfer, such as chemical transfection, have met with limited success of instillation of genetic material into non-proliferating cells in vitro. Among the different kinds of viral vectors, Lentiviral vectors (LVs) have emerged as robust and versatile tool for ex vivo and in vivo gene delivery into multiple cell types including non-dividing cells such as neurons. The capacity of LVs to maintain stable, long-term transgene expression and the substantial flexibility in the design of the expression cassettes account for their increasing use in various pre-clinical and clinical applications. Additionally, LVs have been hugely successful in reprogramming induced pluripotent stem cells (iPSCs). Recent development using LVs in conjunction with a Cre-Lox based reversible system has opened up many new possibilities towards therapeutic application of iPSC technology in various clinical settings. Moreover, improvements in term of biosafety and efficacy, achieved either by modifying the vector design or by involving integration-deficient LVs (IDLVs), have important implications for adoption of LV as the vector of choice for clinical trials. Several human gene therapy clinical trials evaluating the use of LVs for treatment: of human diseases such as Parkinson's disease, β-thalassemia, X-linked adrenoleukodystrophy (ALD), and AIDS are currently ongoing. This review will describe the state of the art achieved by LV technology, its impact on biomedical research, and implications to human clinical trials as therapeutic gene delivery vehicle for a wide range of infectious and genetic diseases.
Collapse
Affiliation(s)
- Pankaj Kumar
- Environment Health Institute, National Environment Agency, BioPolis, Singapore
| | | |
Collapse
|